Biomarker-guided therapy in NSCLC and beyond

In this episode, Dr. Jamie L. Schneider, delves into the practical considerations for targeted therapy in ALK-rearranged non-small cell lung cancer (NSCLC) through an engaging patient case commentary. Join her as she explores the comprehensive diagnostic and treatment approach for a 54-year-old female patient presenting with advanced ALK-positive NSCLC.

This series of 3 podcasts is accredited for 0.25 AMA Type 1 Credit(s) To learn more about the full program, visit targeted-therapies-lung-cancer.ime.springerhealthcare.com for additional resources, including the webinar and downloadable patient case studies.

This program is made possible thanks to an independent educational grant from Roche and Illumina.

References

1. Shaw, A. T. et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med 383, 2018-2029 (2020). https://doi.org/10.1056/NEJMoa2027187


2. Schneider, J. L., Lin, J. J. & Shaw, A. T. ALK-positive lung cancer: a moving target. Nat Cancer 4, 330-343 (2023). https://doi.org/10.1038/s43018-023-00515-0


3. Wu, Y. L. et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 390, 1265-1276 (2024). https://doi.org/10.1056/NEJMoa2310532


4. Peters, S. et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 377, 829-838 (2017). https://doi.org/10.1056/NEJMoa1704795


5. Camidge, D. R. et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 379, 2027-2039 (2018). https://doi.org/10.1056/NEJMoa1810171